Tirofiban HCl hydrate

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 318879

CAS#: 150915-40-5 (HCl hydrate)

Description: Tirofiban is an antiplatelet drug. It belongs to a class of antiplatelet named glycoprotein IIb/IIIa inhibitors. Tirofiban is the first drug candidate whose origins can be traced to a pharmacophore-based virtual screening lead. Tirofiban is indicated to reduce the rate of thrombotic cardiovascular events (combined endpoint of death, myocardial infarction, or refractory ischemia/repeat cardiac procedure) in patients with non-ST elevation acute coronary syndrome (NSTE-ACS).

Price and Availability

Size Price Shipping out time Quantity
50mg USD 450 2 Weeks
100mg USD 750 2 Weeks
200mg USD 1250 2 Weeks
500mg USD 1950 2 Weeks
1g USD 2950 2 Weeks
2g USD 4250 2 Weeks
Inquire bulk and customized quantity

Pricing updated 2021-01-19. Prices are subject to change without notice.

Tirofiban HCl hydrate, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received. Delivery time: overnight (USA/Canada); 3-5 days (worldwide). Shipping fee: from $30.00 (USA); from $45.00 (Canada); from $70.00 (international).

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 318879
Name: Tirofiban HCl hydrate
CAS#: 150915-40-5 (HCl hydrate)
Chemical Formula: C22H39ClN2O6S
Exact Mass: 440.2345
Molecular Weight: 495.072
Elemental Analysis: C, 53.37; H, 7.94; Cl, 7.16; N, 5.66; O, 19.39; S, 6.48

Related CAS #: 150915-40-5 (HCl hydrate)   144494-65-5 (free base)   142373-60-2 (HCl)    

Synonym: Aggrastat; L 700462; L-700,462; MK-383; MK 383; MK383; Tirofiban; Tirofiban hydrochloride monohydrate.

IUPAC/Chemical Name: N-(Butylsulfonyl)-4-(4-(4-piperidyl)butoxy)-L-phenylalanine monohydrochloride monohydrate


InChi Code: InChI=1S/C22H36N2O5S.ClH.H2O/c1-2-3-16-30(27,28)24-21(22(25)26)17-19-7-9-20(10-8-19)29-15-5-4-6-18-11-13-23-14-12-18;;/h7-10,18,21,23-24H,2-6,11-17H2,1H3,(H,25,26);1H;1H2/t21-;;/m0../s1


Technical Data

Solid powder

>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:

Additional Information

Related CAS#
CAS#150915-40-5 (Tirofiban HCl, monohydrate)
CAS#144494-65-5 (Tirofiban free base)


1: King S, Short M, Harmon C. Glycoprotein IIb/IIIa inhibitors: The resurgence of tirofiban. Vascul Pharmacol. 2016 Mar;78:10-6. doi: 10.1016/j.vph.2015.07.008. Epub 2015 Jul 15. Review. PubMed PMID: 26187354.

2: Elcioglu OC, Ozkok A, Akpınar TS, Tufan F, Sezer M, Umman S, Besısık SK. Severe thrombocytopenia and alveolar hemorrhage represent two types of bleeding tendency during tirofiban treatment: case report and literature review. Int J Hematol. 2012 Sep;96(3):370-5. doi: 10.1007/s12185-012-1133-7. Epub 2012 Jul 6. Review. PubMed PMID: 22767141.

3: Guo J, Xu M, Xi Y. Tirofiban-induced diffuse alveolar hemorrhage: after primary angioplasty. Tex Heart Inst J. 2012;39(1):99-103. Review. PubMed PMID: 22412240; PubMed Central PMCID: PMC3298901.

4: Diaz JF, Cardenal R, Gomez-Manchero A, Sanchez-Gonzalez C. Safety and efficacy of tirofiban as adjunctive therapy for patients with ST-elevation myocardial infarction: a comparison versus placebo and abciximab. Cardiovasc Hematol Agents Med Chem. 2011 Jul 1;9(3):147-53. Review. PubMed PMID: 21718242.

5: Valgimigli M, Tebaldi M. Safety evaluation of tirofiban. Expert Opin Drug Saf. 2010 Sep;9(5):801-19. doi: 10.1517/14740338.2010.507189. Review. PubMed PMID: 20670206.

6: Juwana YB, Suryapranata H, Ottervanger JP, van 't Hof AW. Tirofiban for myocardial infarction. Expert Opin Pharmacother. 2010 Apr;11(5):861-6. doi: 10.1517/14656561003690005. Review. PubMed PMID: 20210689.

7: Valgimigli M, Biondi-Zoccai G, Tebaldi M, van't Hof AW, Campo G, Hamm C, ten Berg J, Bolognese L, Saia F, Danzi GB, Briguori C, Okmen E, King SB, Moliterno DJ, Topol EJ. Tirofiban as adjunctive therapy for acute coronary syndromes and percutaneous coronary intervention: a meta-analysis of randomized trials. Eur Heart J. 2010 Jan;31(1):35-49. doi: 10.1093/eurheartj/ehp376. Epub 2009 Sep 14. Review. PubMed PMID: 19755402.

8: van 't Hof AW, Valgimigli M. Defining the role of platelet glycoprotein receptor inhibitors in STEMI: focus on tirofiban. Drugs. 2009;69(1):85-100. doi: 10.2165/00003495-200969010-00006. Review. PubMed PMID: 19192938.

9: Winter JP, Juergens CP. The role of tirofiban in the management of coronary artery disease. Cardiovasc Hematol Disord Drug Targets. 2008 Jun;8(2):138-46. Review. PubMed PMID: 18537601.

10: Mukherjee D, Roffi M. Current strategies with high-dose tirofiban. Expert Opin Drug Metab Toxicol. 2007 Apr;3(2):275-80. Review. PubMed PMID: 17428156.

11: Bukow SC, Daffertshofer M, Hennerici MG. Tirofiban for the treatment of ischaemic stroke. Expert Opin Pharmacother. 2006 Jan;7(1):73-9. Review. PubMed PMID: 16370924.

12: Shanmugam G. Tirofiban and emergency coronary surgery. Eur J Cardiothorac Surg. 2005 Oct;28(4):546-50. Review. PubMed PMID: 16126403.

13: Patel S, Patel M, Din I, Reddy CV, Kassotis J. Profound thrombocytopenia associated with tirofiban: case report and review of literature. Angiology. 2005 May-Jun;56(3):351-5. Review. PubMed PMID: 15889207.

14: Menozzi A, Merlini PA, Ardissino D. Tirofiban in acute coronary syndromes. Expert Rev Cardiovasc Ther. 2005 Mar;3(2):193-206. Review. PubMed PMID: 15853593.

15: Mulot A, Moulin F, Fohlen-Walter A, Angioi M, Sghaier M, Carteaux JP, Lecompte T, de Maistre E. Practical approach to the diagnosis and management of thrombocytopenia associated with tirofiban treatment. Am J Hematol. 2004 Sep;77(1):67-71. Review. PubMed PMID: 15307109.

16: Kondo K, Umemura K. Clinical pharmacokinetics of tirofiban, a nonpeptide glycoprotein IIb/IIIa receptor antagonist: comparison with the monoclonal antibody abciximab. Clin Pharmacokinet. 2002;41(3):187-95. Review. PubMed PMID: 11929319.

17: Doggrell SA. ReoPro rules: results from the 'Do Tirofiban and ReoPro Give Similar Efficacy Trial' (TARGET). Expert Opin Pharmacother. 2001 Sep;2(9):1507-9. Review. PubMed PMID: 11585028.

18: Bergquist PA, Manas D, Hunke WA, Reed RA. Stability and compatibility of tirofiban hydrochloride during simulated Y-site administration with other drugs. Am J Health Syst Pharm. 2001 Jul 1;58(13):1218-23. Review. PubMed PMID: 11449879.

19: Rasmussen S, Husted SE. [Tirofiban (Aggrastat). A non-peptide glycoprotein IIb/IIIa receptor inhibitor]. Ugeskr Laeger. 2001 Jan 22;163(4):461-5. Review. Danish. PubMed PMID: 11218789.

20: Galli M, Maggioni AP, Vassanelli C, Tavazzi L. [The clinical use of the GPIIb/IIIa inhibitors eptifibatide and tirofiban in the treatment of acute coronary syndromes of the "non-ST elevation" type]. Ital Heart J Suppl. 2000 Feb;1(2):202-11. Review. Italian. PubMed PMID: 10731377.